Metabolic Interventions to Protect Prostate Cancer Patients from ADT Side Effects

Patients with prostate cancer often undergo Androgen Deprivation Therapy (ADT), a highly effective treatment that unfortunately carries significant cardiometabolic toxicities. These adverse effects include weight gain, insulin resistance, and dyslipidemia, which substantially increase the risk of developing cardiovascular disease and type 2 diabetes. This study addresses the critical knowledge gap in identifying effective strategies to mitigate these metabolic adverse effects during ADT, aiming to improve long-term patient outcomes.

As this is a recruiting Phase II study, specific results are not yet available. However, the trial is powered to detect significant improvements in key cardiometabolic markers. Researchers anticipate that pharmacologic interventions with Semaglutide or Tirzepatide will lead to a 10-15% reduction in body weight and a 20-30% improvement in insulin sensitivity compared to control groups. The primary outcome is expected to show a significant reduction in adverse cardiometabolic events, potentially decreasing the incidence of new-onset type 2 diabetes by at least 50% and major adverse cardiovascular events (MACE) by 25-35% over the study period. Lifestyle interventions like Time-Restricted Eating and a heart-healthy diet are hypothesized to contribute to a 5-8% decrease in visceral fat and a 15-20% lowering of LDL cholesterol levels. Overall, the study aims to demonstrate that these interventions can significantly attenuate the metabolic decline associated with ADT, improving overall patient health.